Arvinas, Inc.

NASDAQ:ARVN

Biotechnology

Healthcare
$6.77 -1.30%

-$0.10 today

Market cap
$443.01M
Beta
1.75
P/E (TTM)
-2.2
EPS (TTM)
-$3.46
52W Low $6.06High $14.51

Volume 1.09M

Average 0.89M

ARVN Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Arvinas, Inc.NASDAQ: ARVN

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit declines year over year

Q1 FY2026 gross profit of $14.5M fell 92.3% year over year, behind the -79.5% change in trailing-twelve-month gross profit. Sequentially, it rose 74.7% from the prior quarter. Over 3 fiscal years it compounded at +25.1% a year.

Context

  • Gross profit amounted to 98.0% of revenue in FY2025, down 2.0 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -92.3% toward the trailing-twelve-month pace of -79.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.5M+74.7% QoQ
Last fiscal yearDec 2025
$257.4M-2.3% YoY
LTMMar 2026
$87.1M-79.5% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-92.3%——
1 year-2.3%——
3-year CAGR+25.1%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
257.4M USD
Year-over-year change
-2.3%
4-year CAGR
+48.0%

Gross Profit vs competitors

How ARVN compares with its peers on the latest reported figures

  • ARVN's LTM Mar 2026 gross profit of $87.1M is the 3rd highest of the 6 companies compared; the peer median is $40.92M.
  • Its year-over-year change of -79.5% is the lowest of 6, against a peer median of -2.5%.
  • Gross profit amounts to 97.4% of revenue for ARVN, versus a peer median of 94.8%.
ARVN Competitors Peer median
Gross Profit for ARVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$607.18M +545.5%—86.5%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$107.07M +151.2%-5.8%102.0%
ARVNArvinas, Inc.LTM Mar 2026$87.1M -79.5%+25.1%97.4%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$40.92M -74.0%—95.3%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$33.06M -2.5%-3.5%94.8%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$6.28M -73.3%+12.8%22.3%
Peer median (excluding ARVN) $40.92M-2.5%-3.5%94.8%

Competitors are the stored peer set for ARVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue53.6M131.4M78.5M263.4M262.6M
Cost of Revenue00005.2M
Gross Profit53.6M131.4M78.5M263.4M257.4M
Gross Margin100.0%100.0%100.0%100.0%98.0%
Research & Development180.4M315M379.7M348.2M282.9M
Selling, General & Admin61.6M79.6M100.3M165.4M89.4M
Operating Expenses242M394.6M480M513.6M372.3M
Depreciation & Amortization6M8.2M6.7M6.6M5.2M
EBITDA(184.9M)(253.4M)(359.7M)(191.7M)(75.3M)
EBITDA Margin-345.0%-192.8%-458.2%-72.8%-28.7%
Operating Income(188.4M)(263.2M)(401.5M)(250.2M)(114.9M)
Operating Margin-351.5%-200.3%-511.5%-95.0%-43.8%
Interest Income1.8M12M38.8M54.8M22M
Interest Expense100K0000
Other Income / Expenses(2.6M)1.6M35.1M51.9M34.4M
Income Before Tax(191M)(261.6M)(366.4M)(198.3M)(80.5M)
Pre-Tax Margin-356.3%-199.1%-466.8%-75.3%-30.7%
Income Tax Expense020.9M900K600K300K
Net Income(191M)(282.5M)(367.3M)(198.9M)(80.8M)
Net Margin-356.3%-215.0%-467.9%-75.5%-30.8%
EPS (Basic)(3.82)(5.31)(6.62)(2.77)(1.28)
EPS (Diluted)(3.82)(5.31)(6.62)(2.77)(1.28)
Weighted Avg Shares50M53.2M55.5M71.9M64.9M
Weighted Avg Shares (Diluted)50M53.2M55.5M71.9M64.9M

Arvinas, Inc.

NASDAQ:ARVN

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.